Switch to:
Also traded in: UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.71
ICLR's Cash to Debt is ranked lower than
70% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.70 vs. ICLR: 0.71 )
Ranked among companies with meaningful Cash to Debt only.
ICLR' s Cash to Debt Range Over the Past 10 Years
Min: 0.54  Med: 28.53 Max: No Debt
Current: 0.71
Equity to Asset 0.47
ICLR's Equity to Asset is ranked lower than
68% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ICLR: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
ICLR' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.65 Max: 0.77
Current: 0.47
0.44
0.77
Interest Coverage 41.98
ICLR's Interest Coverage is ranked higher than
50% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.98 vs. ICLR: 41.98 )
Ranked among companies with meaningful Interest Coverage only.
ICLR' s Interest Coverage Range Over the Past 10 Years
Min: 17.93  Med: 59.94 Max: 382.53
Current: 41.98
17.93
382.53
F-Score: 7
Z-Score: 4.33
M-Score: -2.74
WACC vs ROIC
6.08%
28.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.33
ICLR's Operating margin (%) is ranked higher than
87% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. ICLR: 18.33 )
Ranked among companies with meaningful Operating margin (%) only.
ICLR' s Operating margin (%) Range Over the Past 10 Years
Min: 3.11  Med: 10.74 Max: 17.88
Current: 18.33
3.11
17.88
Net-margin (%) 15.54
ICLR's Net-margin (%) is ranked higher than
88% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.63 vs. ICLR: 15.54 )
Ranked among companies with meaningful Net-margin (%) only.
ICLR' s Net-margin (%) Range Over the Past 10 Years
Min: 2.42  Med: 8.95 Max: 15.21
Current: 15.54
2.42
15.21
ROE (%) 27.46
ICLR's ROE (%) is ranked higher than
96% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.04 vs. ICLR: 27.46 )
Ranked among companies with meaningful ROE (%) only.
ICLR' s ROE (%) Range Over the Past 10 Years
Min: 3.39  Med: 15.25 Max: 27.96
Current: 27.46
3.39
27.96
ROA (%) 14.39
ICLR's ROA (%) is ranked higher than
95% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. ICLR: 14.39 )
Ranked among companies with meaningful ROA (%) only.
ICLR' s ROA (%) Range Over the Past 10 Years
Min: 2.31  Med: 9.47 Max: 14.75
Current: 14.39
2.31
14.75
ROC (Joel Greenblatt) (%) 111.07
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.88 vs. ICLR: 111.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICLR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.45  Med: 41.07 Max: 121.32
Current: 111.07
12.45
121.32
Revenue Growth (3Y)(%) 12.30
ICLR's Revenue Growth (3Y)(%) is ranked higher than
73% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. ICLR: 12.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ICLR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.6  Med: 12.30 Max: 71.6
Current: 12.3
-14.6
71.6
EBITDA Growth (3Y)(%) 45.00
ICLR's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ICLR: 45.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ICLR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.70 Max: 60.7
Current: 45
0
60.7
EPS Growth (3Y)(%) 63.00
ICLR's EPS Growth (3Y)(%) is ranked higher than
97% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.10 vs. ICLR: 63.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ICLR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.9  Med: 5.90 Max: 93.9
Current: 63
-33.9
93.9
» ICLR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ICLR Guru Trades in Q2 2015

Jim Simons 539,200 sh (+2.07%)
Chuck Royce 156,600 sh (-11.72%)
Ron Baron 1,138,759 sh (-22.48%)
» More
Q3 2015

ICLR Guru Trades in Q3 2015

Ron Baron 1,138,759 sh (unchged)
Chuck Royce 150,700 sh (-3.77%)
Jim Simons 377,460 sh (-30.00%)
» More
Q4 2015

ICLR Guru Trades in Q4 2015

Steven Cohen 77,100 sh (New)
Chuck Royce 150,700 sh (unchged)
Ron Baron 1,084,201 sh (-4.79%)
Jim Simons 113,700 sh (-69.88%)
» More
Q1 2016

ICLR Guru Trades in Q1 2016

Jeremy Grantham 8,100 sh (New)
Steven Cohen Sold Out
Chuck Royce 143,700 sh (-4.64%)
Ron Baron 931,953 sh (-14.04%)
Jim Simons 65,700 sh (-42.22%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LSE:0H1Z, NYSE:BIO, NAS:BRKR, NYSE:CRL, OSTO:SOBI, NAS:VWR » details
Traded in other countries:0NBW.UK,
Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries.

Icon PLC was incorporated in 1990. The Company is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The Company organized, operated and assessed its business in two segments, the clinical research segment and the central laboratory segment. The Clinical Research business specializes in the planning, management, execution and analysis of Phase I - IV clinical trials, ranging from small studies to complex, multinational projects. It also conduct various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial Specific clinical research services. The Company provides laboratory services through its central laboratory business, which includes the Company's central laboratories located in Dublin, New York, India, Singapore and China. The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Belgium, Turkey, Poland, Czech Republic, Lithuania, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa. The Company's principal competitors are Covance Inc., PAREXEL International Corporation, Pharmaceutical Product Development Inc., Quintiles Transnational Corporation, inVentiv Health , PRA and INC Research.

Guru Investment Theses on Icon PLC

Meridian Funds Comments on Icon PLC - Dec 17, 2014

ICON (ICLR) manages clinical trials for the biotech, pharmaceutical and medical device industries. Our investment in the company materialized when earnings were pressured by an industry slowdown in clinical trials at the same time that ICON was investing in its own capacity expansion. We viewed the slowdown in demand as temporary, caused by the elimination of many duplicative drug development programs. In addition, we thought ICON’s investments in technology positioned the company to gain market share in a growing industry as pharmaceutical customers increasingly outsourced clinical trial work. Strong stock performance in the quarter was driven by revenue and margins coming in above street estimates and a positive management outlook. We continue to hold shares in ICON based on its positioning as a technology leader in the clinical trial industry and the potential to further expand operating margins

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 16.25
ICLR's P/E(ttm) is ranked higher than
79% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.05 vs. ICLR: 16.25 )
Ranked among companies with meaningful P/E(ttm) only.
ICLR' s P/E(ttm) Range Over the Past 10 Years
Min: 8.07  Med: 17.81 Max: 78.79
Current: 16.25
8.07
78.79
Forward P/E 13.19
ICLR's Forward P/E is ranked higher than
95% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. ICLR: 13.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.25
ICLR's PE(NRI) is ranked higher than
79% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.16 vs. ICLR: 16.25 )
Ranked among companies with meaningful PE(NRI) only.
ICLR' s PE(NRI) Range Over the Past 10 Years
Min: 7.99  Med: 17.77 Max: 78.03
Current: 16.25
7.99
78.03
Price/Owner Earnings (ttm) 15.62
ICLR's Price/Owner Earnings (ttm) is ranked higher than
81% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.47 vs. ICLR: 15.62 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ICLR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.99  Med: 22.35 Max: 437.5
Current: 15.62
5.99
437.5
P/B 4.48
ICLR's P/B is ranked lower than
65% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ICLR: 4.48 )
Ranked among companies with meaningful P/B only.
ICLR' s P/B Range Over the Past 10 Years
Min: 0.46  Med: 2.36 Max: 5.6
Current: 4.48
0.46
5.6
P/S 2.56
ICLR's P/S is ranked higher than
58% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. ICLR: 2.56 )
Ranked among companies with meaningful P/S only.
ICLR' s P/S Range Over the Past 10 Years
Min: 0.58  Med: 1.52 Max: 3.31
Current: 2.56
0.58
3.31
PFCF 17.58
ICLR's PFCF is ranked higher than
69% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.05 vs. ICLR: 17.58 )
Ranked among companies with meaningful PFCF only.
ICLR' s PFCF Range Over the Past 10 Years
Min: 5.84  Med: 19.74 Max: 500.21
Current: 17.58
5.84
500.21
POCF 14.65
ICLR's POCF is ranked higher than
64% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.45 vs. ICLR: 14.65 )
Ranked among companies with meaningful POCF only.
ICLR' s POCF Range Over the Past 10 Years
Min: 4.65  Med: 15.41 Max: 85.38
Current: 14.65
4.65
85.38
EV-to-EBIT 13.25
ICLR's EV-to-EBIT is ranked higher than
73% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.15 vs. ICLR: 13.25 )
Ranked among companies with meaningful EV-to-EBIT only.
ICLR' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.6  Med: 14.85 Max: 48
Current: 13.25
1.6
48
EV-to-EBITDA 10.99
ICLR's EV-to-EBITDA is ranked higher than
67% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.21 vs. ICLR: 10.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICLR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.9  Med: 11.10 Max: 23.6
Current: 10.99
0.9
23.6
PEG 0.52
ICLR's PEG is ranked higher than
98% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.63 vs. ICLR: 0.52 )
Ranked among companies with meaningful PEG only.
ICLR' s PEG Range Over the Past 10 Years
Min: 0.38  Med: 1.44 Max: 8.22
Current: 0.52
0.38
8.22
Shiller P/E 35.60
ICLR's Shiller P/E is ranked higher than
61% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.91 vs. ICLR: 35.60 )
Ranked among companies with meaningful Shiller P/E only.
ICLR' s Shiller P/E Range Over the Past 10 Years
Min: 9.95  Med: 19.99 Max: 48.99
Current: 35.6
9.95
48.99
Current Ratio 1.66
ICLR's Current Ratio is ranked lower than
71% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ICLR: 1.66 )
Ranked among companies with meaningful Current Ratio only.
ICLR' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.66
1.12
3.61
Quick Ratio 1.66
ICLR's Quick Ratio is ranked lower than
64% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. ICLR: 1.66 )
Ranked among companies with meaningful Quick Ratio only.
ICLR' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.66
1.12
3.61
Days Sales Outstanding 83.32
ICLR's Days Sales Outstanding is ranked lower than
69% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 83.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICLR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.88  Med: 87.76 Max: 94.82
Current: 83.32
66.88
94.82
Days Payable 129.91
ICLR's Days Payable is ranked higher than
82% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. ICLR: 129.91 )
Ranked among companies with meaningful Days Payable only.
ICLR' s Days Payable Range Over the Past 10 Years
Min: 1.98  Med: 11.26 Max: 130.79
Current: 129.91
1.98
130.79

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.02
ICLR's Price/Tangible Book is ranked lower than
92% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. ICLR: 20.02 )
Ranked among companies with meaningful Price/Tangible Book only.
ICLR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.64  Med: 3.33 Max: 40.36
Current: 20.02
0.64
40.36
Price/Projected FCF 1.56
ICLR's Price/Projected FCF is ranked higher than
70% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. ICLR: 1.56 )
Ranked among companies with meaningful Price/Projected FCF only.
ICLR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.71 Max: 6.7
Current: 1.56
0.52
6.7
Price/Median PS Value 1.69
ICLR's Price/Median PS Value is ranked lower than
86% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. ICLR: 1.69 )
Ranked among companies with meaningful Price/Median PS Value only.
ICLR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 0.94 Max: 1.98
Current: 1.69
0.38
1.98
Price/Peter Lynch Fair Value 0.65
ICLR's Price/Peter Lynch Fair Value is ranked higher than
96% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.37 vs. ICLR: 0.65 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ICLR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.2  Med: 1.33 Max: 3.22
Current: 0.65
0.2
3.22
Price/Graham Number 3.80
ICLR's Price/Graham Number is ranked lower than
61% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. ICLR: 3.80 )
Ranked among companies with meaningful Price/Graham Number only.
ICLR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.42  Med: 1.59 Max: 5.9
Current: 3.8
0.42
5.9
Earnings Yield (Greenblatt) (%) 7.61
ICLR's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.40 vs. ICLR: 7.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICLR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 6.75 Max: 63.7
Current: 7.61
2.1
63.7
Forward Rate of Return (Yacktman) (%) 42.51
ICLR's Forward Rate of Return (Yacktman) (%) is ranked higher than
97% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.36 vs. ICLR: 42.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ICLR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -14.9  Med: 9.30 Max: 42.6
Current: 42.51
-14.9
42.6

More Statistics

Revenue (TTM) (Mil) $1,587
EPS (TTM) $ 4.23
Beta0.59
Short Percentage of Float3.37%
52-Week Range $62.31 - 84.14
Shares Outstanding (Mil)55.07

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,698 1,825 1,912
EPS ($) 4.68 5.20 5.82
EPS without NRI ($) 4.68 5.20 5.82
EPS Growth Rate
(3Y to 5Y Estimate)
11.63%
» More Articles for ICLR

Headlines

Articles On GuruFocus.com
Dynamite Comes in Small Packages: 10 Small Caps to Get Explosive Returns Apr 01 2016 
Probable Gainers Of A European Market Bounce Back Jan 25 2015 
Meridian Funds Comments on Icon PLC Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 

More From Other Websites
ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research... May 16 2016
ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research... May 16 2016
ETF’s with exposure to ICON Plc : April 28, 2016 Apr 28 2016
ICON Plc :ICLR-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 27 2016
ICON Plc breached its 50 day moving average in a Bearish Manner : ICLR-US : April 27, 2016 Apr 27 2016
What’s the Deal With These 5 Tanking Stocks? Apr 26 2016
Edited Transcript of ICLR earnings conference call or presentation 26-Apr-16 1:00pm GMT Apr 26 2016
ICON PLC Earnings Call scheduled for 9:00 am ET today Apr 26 2016
Q1 2016 ICON PLC Earnings Release - Time Not Supplied Apr 26 2016
Icon PLC beats 1Q profit forecasts Apr 26 2016
Icon PLC beats 1Q profit forecasts Apr 26 2016
ICON Reports First Quarter 2016 Results Apr 26 2016
ICON Reports First Quarter 2016 Results Apr 26 2016
ICON Reports First Quarter 2016 Results Apr 26 2016
Breakout Watch: INC Research Nears Buy Ahead Of Q1 Earnings Apr 14 2016
Goldman Sachs Gives These 4 Cheap Stocks a Thumbs Up and So Do the Charts Apr 06 2016
ICON PLC Financials Mar 29 2016
Mr. Thomas Lynch Notifies ICON of His Retirement as Chairman and That He Will Not Stand for... Mar 29 2016
Mr. Thomas Lynch Notifies ICON of His Retirement as Chairman and That He Will Not Stand for... Mar 29 2016
Envision Healthcare (EVHC) Set to Buy EPMG in Michigan Mar 18 2016
ICON and ICHOM to Roll out GLOBE Benchmarking Program Mar 10 2016
ICON Selected by the International Consortium for Health Outcomes Measurement to Help Advance... Mar 08 2016
ICON Selected by the International Consortium for Health Outcomes Measurement to Help Advance... Mar 08 2016
ICON Plc – Value Analysis (NASDAQ:ICLR) : March 1, 2016 Mar 01 2016
ICON Plc breached its 50 day moving average in a Bullish Manner : ICLR-US : February 29, 2016 Feb 29 2016
ICON Selected by Genomics England to Support the Largest Genome Sequencing Project of Its Kind for... Feb 25 2016
ICON Plc Earnings Analysis: 2015 By the Numbers Feb 24 2016
ICON (ICLR) Beats Q4 Earnings, Misses Revenue Estimates Feb 24 2016
Icon PLC tops 4Q profit forecasts Feb 23 2016
ICON selected by Genomics England to support the largest genome sequencing project of its kind for... Feb 09 2016
ICON Releases Flex Advantage to Enhance Patient Randomisation and Clinical Supply Management in... Jan 19 2016
ICON Secures Investment Grade Credit Ratings Jan 05 2016
ICON Secures Investment Grade Credit Ratings Jan 05 2016
ICON plc Announces Private Placement of US$350,000,000 of Senior Notes Dec 16 2015
ICON Accelerates Site Activation Timelines by up to 25% Dec 09 2015
ICON Acquires PMG Research Inc. Dec 07 2015
ICON Acquires PMG Research, Inc. Dec 07 2015
ICON Announces the Appointment of Dr. Steve Cutler to Board of Directors Nov 25 2015
ICON Partners with iCardiac Technologies to Provide an Earlier and More Precise Method for... Nov 03 2015
ICON Reports Third Quarter 2015 Oct 27 2015
Icon PLC beats 3Q profit forecasts Oct 27 2015
ICON Reports Third Quarter 2015 Oct 27 2015
ICON Strengthens its Leadership Team in Asia Pacific with Two Key Appointments Oct 22 2015
ICON Receives Finalist Nomination for the 2015 Scrip Awards Sep 21 2015
ICON and IBM to Revolutionise Clinical Trial Feasibility, Patient Recruitment and Study Start-up... Sep 10 2015
ICON and IBM to Revolutionise Clinical Trial Feasibility, Patient Recruitment and Study Start-up... Sep 10 2015
ICON Forms Partnership with Mereo BioPharma for Clinical Development Jul 30 2015
Icon PLC beats 2Q profit forecasts Jul 28 2015
ICON Reports Second Quarter 2015 Jul 28 2015
ICON Reports Second Quarter 2015 Jul 28 2015
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting Jul 27 2015
Cancer Genetics, Inc. Announces a Partnership with ICON Jul 09 2015
ICON Launches Firecrest Patient Portal to Enhance Education around Informed Consent Jun 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)